Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Status:
Completed
Trial end date:
2016-11-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal
antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients
with high-risk Non-Hodgkin's Lymphoma (NHL).